Q32 Bio Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jodie Pope Morrison
- Full Time Employees
- 24
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 830 Winter Street Waltham MA United States of America 02451
- IPO Date
- Mar 28, 2018
- CIK
- 0001661998
- Website
- q32bio.com
- Similar Companies
- Business
- Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts, develops biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to restore healthy immune balance in patients with severe autoimmune and inflammatory diseases. The company's lead product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling; it is currently advancing in a Phase 2 program, including the ongoing SIGNAL-AA Phase 2a trial, for alopecia areata, following promising Phase 2a results showing clinical activity, biomarker inhibition, and a well-tolerated safety profile, with U.S. FDA Fast Track designation. Additional pipeline assets include the complement inhibitor platform featuring development candidate ADX-096, a C3d-CR1 fusion protein, alongside earlier-stage C3d monoclonal antibody fusions and nanobodies for tissue-targeted complement inhibition in renal and other complement-mediated diseases such as lupus nephritis, immunoglobulin A nephropathy, and complement component 3 glomerulopathy. Q32 Bio operates primarily in the United States, targeting patients with high unmet needs in T cell-mediated and complement-driven pathologies. In March 2024, the company completed a merger with Homology Medicines Inc. and a concurrent $42 million private placement financing with investors including OrbiMed, Atlas Venture, Abingworth, and Bristol Myers Squibb, providing cash reserves to fund operations through mid-2026 and enabling public trading under the QTTB ticker; formerly known as Admirx Inc., it changed its name to Q32 Bio in April 2020.
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
Q32 Bio: Bempikibart's Progress Keeps Me Bullish
Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Why Q32 Bio Stock Skyrocketed Today
Q32 Bio: 'Strong Buy' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Why Q32 Bio investors should take profits in the stock after 81% rally
Q32 Bio's Bempikibart Shows Durable Hair Regrowth in Phase 2 Alopecia Study
Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
Q32 Bio Announces $55 Million Private Placement Financing
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?
Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive